Colossal tackles devil facial tumour disease with oral vaccine
The Colossal Foundation partners with University of Tasmania to develop a field-ready vaccine and explore genetic resistance using a dunnart colony.
See the latest news and media coverage for Colossal. We track all announcements, press releases, and industry mentions in real time, all in one place.
Genetics and biosciences company focused on de-extinction
colossal.comLast updated
In short: Colossal reached de-extinction milestones, reporting the first dire wolf births and developing artificial eggs to aid species revival.
The Colossal Foundation partners with University of Tasmania to develop a field-ready vaccine and explore genetic resistance using a dunnart colony.
The partnership aims to collect genetic material from over 2100 listed species for conservation and potential de-extinction.
The technology spreads infertility through the population, potentially clearing the parasite in months instead of decades.
Twenty birds bred in Europe are being sent to Vietnam to restore the wild population.
Colossal already aims for $30,000M with AI and synthetic biology Colossal Biosciences, the Dallas-based startup working to 'resurrect' the woolly mammoth...
Now valued at $3.8 billion, the Colossal Biosciences spinout says genomic records from living and extinct species can fo...
Shaires Holdings Ltd LSE:SHR...
"The red wolf has long been a contentious species. The debate over its preservation got even messier last year, when Colossal said it had cloned...
Track Colossal and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.